



## LIRAGLUTIDE : SEMAGLUTIDE

**Liraglutide** and **Semaglutide** are glucagon-like peptide-1 (GLP-1) receptor agonists which promote weight loss by decreasing food intake and increasing feelings of fullness. These are usually used in combination with Metformin (Glucophage) for weight loss, insulin resistance and diabetes.

The initial discovery of these gut hormones with important effects on glycemic control and body weight regulation led to efforts to make them commercially available and therapeutically effective for people with type 2 diabetes and obesity.

**Liraglutide** and **Semaglutide both** affect the GLP-1 receptor, which is expressed in the pancreas, gastrointestinal tract, heart, lungs, kidneys, and brain. The receptors in the pancreas and brain have been shown to account for improved glycemic control and body weight

These results become evident with the use of liraglutide and semaglutide. In addition, both liraglutide and semaglutide also positively affect cardiovascular outcomes in patients with diabetes type 2.

Weight loss through an effect in reducing energy intake led to the approval of liraglutide and semaglutide for the treatment of obesity.

**Liraglutide** and **Semaglutide** have made an impressive contribution to the management and improvements of glycemic control, body weight, blood pressure, cholesterol and other lipids, beta-cell function in the pancreas, and cardiovascular outcomes in patients.

